( AMEX:CANF, TelAviv:CFBI )

News from Can-Fite BioPharma Ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 15, 2017, 07:00 ET Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...


Jun 08, 2017, 07:00 ET Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...


Jun 05, 2017, 07:00 ET Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...


Jun 01, 2017, 07:00 ET New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...


May 30, 2017, 07:00 ET Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...


May 16, 2017, 07:00 ET Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...


May 03, 2017, 07:00 ET Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...


Apr 25, 2017, 07:00 ET Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board

- Barzilai Medical Center in Israel ready to enroll patients - IRB approvals in European and Canadian medical centers expected to...


Mar 31, 2017, 07:00 ET Can-Fite Reports 2016 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...


Feb 28, 2017, 07:00 ET New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...


Feb 08, 2017, 07:00 ET Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...


Jan 19, 2017, 07:29 ET Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...


Jan 09, 2017, 07:00 ET Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Dec 21, 2016, 07:00 ET Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Dec 16, 2016, 07:00 ET New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Nov 25, 2016, 07:00 ET Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Nov 16, 2016, 07:00 ET American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Nov 09, 2016, 07:00 ET Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Nov 07, 2016, 07:00 ET Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Nov 01, 2016, 07:00 ET Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Oct 25, 2016, 07:15 ET Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Oct 13, 2016, 07:00 ET Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Sep 20, 2016, 07:00 ET Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed...


Sep 13, 2016, 07:00 ET Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...


Sep 07, 2016, 07:00 ET Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...